$TNYA
Tenaya Therapeutics Inc

2023 Q3 Form 10-Q Financial Statement

#000095017023040651 Filed on August 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.830M $8.627M $7.743M
YoY Change 3.85% 11.42% 78.78%
% of Gross Profit
Research & Development $23.09M $26.48M $20.88M
YoY Change -2.81% 26.83% 91.42%
% of Gross Profit
Depreciation & Amortization $2.180M $2.195M $1.297M
YoY Change 4.46% 69.24% 76.46%
% of Gross Profit
Operating Expenses $30.92M $35.10M $28.62M
YoY Change -1.21% 22.66% 87.83%
Operating Profit -$30.92M -$35.10M -$28.62M
YoY Change -1.21% 22.66% 87.83%
Interest Expense $1.780M $1.837M $222.0K
YoY Change 198.66% 727.48% 2366.67%
% of Operating Profit
Other Income/Expense, Net $1.777M $1.835M $222.0K
YoY Change 195.18% 726.58% 722.22%
Pretax Income -$29.14M -$33.27M -$28.40M
YoY Change -5.06% 17.16% 86.7%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$29.14M -$33.27M -$28.40M
YoY Change -5.06% 17.16% 86.7%
Net Earnings / Revenue
Basic Earnings Per Share -$0.39 -$0.45 -$0.69
Diluted Earnings Per Share -$0.39 -$0.45 -$687.5K
COMMON SHARES
Basic Shares Outstanding 67.87M 66.87M 41.31M
Diluted Shares Outstanding 73.92M 73.40M 41.30M

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $121.8M $132.5M $180.9M
YoY Change -18.5% -26.76% 61.7%
Cash & Equivalents $82.15M $75.57M $31.01M
Short-Term Investments $39.60M $56.94M $149.9M
Other Short-Term Assets $5.100M $6.401M $4.777M
YoY Change -33.04% 34.0% 257.56%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $126.8M $138.9M $185.7M
YoY Change -19.25% -25.2% 64.01%
LONG-TERM ASSETS
Property, Plant & Equipment $45.13M $47.04M $53.01M
YoY Change -13.53% -11.27% 112.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $6.400M $19.14M
YoY Change
Other Assets $5.734M $5.540M $3.710M
YoY Change 23.31% 49.33% -37.13%
Total Long-Term Assets $66.57M $81.85M $70.24M
YoY Change -3.86% 16.53% 60.82%
TOTAL ASSETS
Total Short-Term Assets $126.8M $138.9M $185.7M
Total Long-Term Assets $66.57M $81.85M $70.24M
Total Assets $193.4M $220.8M $255.9M
YoY Change -14.54% -13.74% 63.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.902M $8.484M $5.347M
YoY Change 11.11% 58.67% 6.51%
Accrued Expenses $10.32M $8.986M $9.498M
YoY Change 23.04% -5.39% 202.2%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $19.38M $20.92M $18.74M
YoY Change 9.38% 11.61% 91.23%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $246.0K $240.0K $217.0K
YoY Change 10.31% 10.6% 7133.33%
Total Long-Term Liabilities $246.0K $240.0K $217.0K
YoY Change 10.31% 10.6% 7133.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.38M $20.92M $18.74M
Total Long-Term Liabilities $246.0K $240.0K $217.0K
Total Liabilities $28.51M $30.81M $32.06M
YoY Change -4.9% -3.89% 29.83%
SHAREHOLDERS EQUITY
Retained Earnings -$373.3M -$344.2M -$215.0M
YoY Change 51.93% 60.09% 93.52%
Common Stock $7.000K $7.000K $4.000K
YoY Change 75.0% 75.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $164.9M $189.9M $223.9M
YoY Change
Total Liabilities & Shareholders Equity $193.4M $220.8M $255.9M
YoY Change -14.54% -13.74% 63.12%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$29.14M -$33.27M -$28.40M
YoY Change -5.06% 17.16% 86.7%
Depreciation, Depletion And Amortization $2.180M $2.195M $1.297M
YoY Change 4.46% 69.24% 76.46%
Cash From Operating Activities -$23.64M -$26.22M -$25.43M
YoY Change -14.21% 3.11% 111.58%
INVESTING ACTIVITIES
Capital Expenditures $10.00K $208.0K -$7.176M
YoY Change -100.25% -102.9% 121.76%
Acquisitions
YoY Change
Other Investing Activities $30.50M $25.29M $37.39M
YoY Change -13.1% -32.35%
Cash From Investing Activities $30.48M $25.09M $30.21M
YoY Change -1.79% -16.96% -1033.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 4.179M 260.0K
YoY Change -100.0% 1507.31% -120.03%
NET CHANGE
Cash From Operating Activities -23.64M -26.22M -25.43M
Cash From Investing Activities 30.48M 25.09M 30.21M
Cash From Financing Activities 0.000 4.179M 260.0K
Net Change In Cash 6.840M 3.044M 5.040M
YoY Change 96.33% -39.6% -130.45%
FREE CASH FLOW
Cash From Operating Activities -$23.64M -$26.22M -$25.43M
Capital Expenditures $10.00K $208.0K -$7.176M
Free Cash Flow -$23.65M -$26.43M -$18.25M
YoY Change 0.67% 44.78% 107.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001858848
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40656
dei Entity Registrant Name
EntityRegistrantName
TENAYA THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-3789973
dei Entity Address Address Line1
EntityAddressAddressLine1
171 Oyster Point Boulevard
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 500
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
825-6990
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
TNYA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
67865158
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75565000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95272000
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
56940000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
91255000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6401000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7227000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
138906000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
193754000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
47039000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
51032000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10133000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11663000
CY2023Q2 us-gaap Long Term Investments
LongTermInvestments
19136000
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
17703000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5540000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4793000
CY2023Q2 us-gaap Assets
Assets
220754000
CY2022Q4 us-gaap Assets
Assets
278945000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
8484000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9578000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8986000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10664000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3447000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4006000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
20917000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
24248000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9657000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11093000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
240000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
228000
CY2023Q2 us-gaap Liabilities
Liabilities
30814000
CY2022Q4 us-gaap Liabilities
Liabilities
35569000
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
7000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
534470000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
522945000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-333000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-378000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-344204000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-279198000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
189940000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
243376000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
220754000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
278945000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26477000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20876000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
52082000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45031000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8627000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7743000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16745000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14742000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
35104000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
28619000
us-gaap Operating Expenses
OperatingExpenses
68827000
us-gaap Operating Expenses
OperatingExpenses
59773000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-35104000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-28619000
us-gaap Operating Income Loss
OperatingIncomeLoss
-68827000
us-gaap Operating Income Loss
OperatingIncomeLoss
-59773000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1837000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
222000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3810000
us-gaap Investment Income Interest
InvestmentIncomeInterest
321000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1835000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
222000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3821000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
320000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33269000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28397000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-65006000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-59453000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-33269000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-28397000
us-gaap Net Income Loss
NetIncomeLoss
-65006000
us-gaap Net Income Loss
NetIncomeLoss
-59453000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-213000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-108000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
45000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-598000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33482000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28505000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-64961000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-60051000
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.89
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.89
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.44
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73399847
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73399847
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41302157
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41302157
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73249702
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73249702
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41285168
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41285168
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
243376000
CY2023Q1 tnya Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
1000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3514000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
258000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-31737000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
215412000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
282000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
29000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3831000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-213000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-33269000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
189940000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
278526000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17000
CY2022Q1 tnya Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
6000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2094000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-490000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-31056000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
249097000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
230000
CY2022Q2 tnya Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
5000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3012000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-108000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-28397000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
223867000
us-gaap Profit Loss
ProfitLoss
-65006000
us-gaap Profit Loss
ProfitLoss
-59453000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4325000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2263000
tnya Amortization Of Premium On Marketable Securities
AmortizationOfPremiumOnMarketableSecurities
-1056000
tnya Amortization Of Premium On Marketable Securities
AmortizationOfPremiumOnMarketableSecurities
253000
us-gaap Share Based Compensation
ShareBasedCompensation
7345000
us-gaap Share Based Compensation
ShareBasedCompensation
5106000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1530000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
795000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-105000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-28000
tnya Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
-733000
tnya Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
438000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
726000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
132000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-223000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2120000
tnya Increase Decrease In Accrued Liabilities And Other Current Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
-1542000
tnya Increase Decrease In Accrued Liabilities And Other Current Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
711000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1995000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1206000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
7000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-56510000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-54186000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
837000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15771000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
40998000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
65135000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
74984000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
127550000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
3000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
33146000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
46644000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3868000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
501000
tnya Proceeds From Exercise Of Stock Options And Employee Stock Purchase Plan
ProceedsFromExerciseOfStockOptionsAndEmployeeStockPurchasePlan
311000
tnya Proceeds From Exercise Of Stock Options And Employee Stock Purchase Plan
ProceedsFromExerciseOfStockOptionsAndEmployeeStockPurchasePlan
275000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3678000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
275000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-19686000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7267000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
95671000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
38676000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
75985000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
31409000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75565000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31010000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
420000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
399000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75985000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31409000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
44000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3060000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-344200000
us-gaap Net Income Loss
NetIncomeLoss
-65000000
us-gaap Net Income Loss
NetIncomeLoss
-59500000
CY2023Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
151600000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accrued liabilities, income tax valuation allowance and stock-based compensation.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Management bases its estimates on historical experience, the current economic environment, and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</span></p>
tnya Impairment Charges On Marketable Securities Related To Other Than Temporary
ImpairmentChargesOnMarketableSecuritiesRelatedToOtherThanTemporary
0
CY2023Q2 us-gaap Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue
56900000
CY2023Q2 tnya Available For Sale Securities Debt Maturities One And Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesOneAndTwoYearsFairValue
19100000
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
67040000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
66708000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
20001000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15676000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
47039000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
51032000
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2200000
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1300000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4300000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2300000
CY2023Q2 tnya Accrued Compensation And Related Expenses
AccruedCompensationAndRelatedExpenses
4778000
CY2022Q4 tnya Accrued Compensation And Related Expenses
AccruedCompensationAndRelatedExpenses
6299000
CY2023Q2 tnya Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
2206000
CY2022Q4 tnya Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
3214000
CY2023Q2 tnya Accrued Facility Management Service Fee
AccruedFacilityManagementServiceFee
608000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
500000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
482000
CY2023Q2 tnya Accrued Employee Stock Purchase Plan Deduction Liability
AccruedEmployeeStockPurchasePlanDeductionLiability
116000
CY2022Q4 tnya Accrued Employee Stock Purchase Plan Deduction Liability
AccruedEmployeeStockPurchasePlanDeductionLiability
124000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
778000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
545000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8986000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10664000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1091000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
832000
us-gaap Operating Lease Cost
OperatingLeaseCost
2181000
us-gaap Operating Lease Cost
OperatingLeaseCost
1534000
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
322000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
353000
us-gaap Variable Lease Cost
VariableLeaseCost
595000
us-gaap Variable Lease Cost
VariableLeaseCost
591000
CY2022Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
240000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
5000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
465000
CY2023Q2 us-gaap Lease Cost
LeaseCost
1413000
CY2022Q2 us-gaap Lease Cost
LeaseCost
1425000
us-gaap Lease Cost
LeaseCost
2781000
us-gaap Lease Cost
LeaseCost
2590000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2224000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.94
tnya Cash Paid For Amounts Included In The Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities
2646000
tnya Cash Paid For Amounts Included In The Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities
1663000
CY2023Q2 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P5Y6M
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.094
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.95
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2577000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3910000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2445000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1386000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1428000
CY2023Q2 tnya Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
5477000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
17223000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4119000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
13104000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P10Y
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.94
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.95
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.96
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.97
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.96
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.97
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.034
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.039
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.028
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.034
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.034
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.04
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.016
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.034
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3831000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3012000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7345000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5106000
CY2023Q2 tnya Pre Funded Warrants Exercised
PreFundedWarrantsExercised
302517
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
18202129
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9484387
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5248962

Files In Submission

Name View Source Status
0000950170-23-040651-index-headers.html Edgar Link pending
0000950170-23-040651-index.html Edgar Link pending
0000950170-23-040651.txt Edgar Link pending
0000950170-23-040651-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tnya-20230630.htm Edgar Link pending
tnya-20230630.xsd Edgar Link pending
tnya-ex31_1.htm Edgar Link pending
tnya-ex31_2.htm Edgar Link pending
tnya-ex32_1.htm Edgar Link pending
tnya-ex3_1.htm Edgar Link pending
tnya-20230630_def.xml Edgar Link unprocessable
tnya-20230630_lab.xml Edgar Link unprocessable
tnya-20230630_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
tnya-20230630_cal.xml Edgar Link unprocessable
tnya-20230630_pre.xml Edgar Link unprocessable